Navigation Links
Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
Date:12/13/2011

ZFN-mediated repair of the human Factor IX gene, substantially expanding the potential of the approach.

The study was conducted in the laboratory of Katherine High, M.D., Investigator, Howard Hughes Medical Institute, Professor of Pediatrics, University of Pennsylvania School of Medicine and Director, Center for Cellular and Molecular Therapeutics at The Children's Hospital of Philadelphia, in collaboration with Sangamo scientists.

In a second study presented at the meeting, ZFN gene disruption was used to generate a next generation cancer immunotherapy by enhancing the targeted killing activity and safety profile of the product.

Abst. No. 667 - TCR Gene Editing Results in Effective Immunotherapy of Leukemia without the Development of GvHD (Oral Session: 801)

Cancer immunotherapy uses CD8 T-cells that have been engineered to express high avidity T-cell receptor (TCR) genes isolated from tumor-specific lymphocytes.  The engineered CD8 T-cells are then able to attack the tumor. Problems can arise with this approach because the expression of the CD8 T-cell's own TCR gene interferes with expression of the inserted tumor-specific TCR gene.  This interaction limits the potency of this cellular therapy but, more importantly, it can also make the cells "self-reactive" leading to graft versus host disease (GvHD).

In this study, ZFNs were used to disrupt the native TCR genes in these tumor-directed CD8 T-cells resulting in an enhanced immunotherapeutic product with potent cancer cell-killing activity and the elimination of GvHD in a mouse model.  These studies were performed in the laboratory of Chiara Bonini, M.D., Head of the Experimental Hematology Unit, San Raffaele Hospital, Milan, in collaboration with Luigi Naldini, Head of TIGET, San Raffaele Hospital, and Sangamo scientists.

"We continue to develop our ZFP Therapeutic pipeline and, on the strength of our success in mouse models, have advanced ou
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sangamo BioSciences Announces Presentation at the Lazard Capital Markets 8th Annual Healthcare Conference
2. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
3. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
4. Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech Industry Conference
5. Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference
6. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
7. Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology
8. Sangamo BioSciences Announces Second Quarter 2011 Conference Call and Webcast
9. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
10. Sangamo Announces Pricing of Public Offering of Common Stock
11. Sangamo Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... The fully automated supercritical fluidic ... sequentially analyze up to 48 samples utilizing automatic ... of targets by mass spectrometry. , The ... measurement requirements of a wide range of applications, ... and search for disease biomarkers, additives in forming ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE MKT: ... of biosimilar therapeutics, today announced that it will be ... Marquis on March 2 nd at 3pm PST. Patrick ... a panel discussing the current state of the biosimilar ... . For more information on CALBIO ...
(Date:2/27/2015)... 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... with patients and health care advocates in the United ... Day®. Rare Disease Day is dedicated to elevating ... the special challenges faced by patients with rare diseases ... proud to stand alongside patients and caregivers representing the ...
(Date:2/27/2015)... PureTech , a science and technology R&D company focused  ... in the healthcare sector, announced today the appointment of ... the Board of Directors of Sanofi, to its Board ... pleasure to know Chris for many years and I ... more closely now," said Dr. Robert Langer , ...
Breaking Biology Technology:Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4
... , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.528 01/2002 , ... , , , , ... , Cell type , Bacteria, gram ...
... , , , , Multiporator / Electroporator 2510 , , , , ... Transformation Protocol , Protocol No. 4308 915.524 03/2002 , ... , , , , ... , Cell type , Bacteria, gram positive, ...
... , , , Multiporator / Electroporator 2510 , , , , , ... Transformation Protocol , Protocol No. 4308 915.523 03/2002 , ... , , , Microorganism ... Cell type , Bacteria, gram positive, ...
Cached Biology Technology:Pseudomonas aeruginosa 2Mycobacterium tuberculosis 2Mycobacterium avium 2
(Date:2/5/2015)... MOUNTAIN VIEW, Calif. , Feb. 3, 2015 ... screen printer technology, demand from industries such as ... the global market for surface mount technology (SMT) ... manual equipment to automatic control will push the ... glue dispensers will remain steady as glue dispensers ...
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ... in general the State of Washington,s ... a new enrollment and central issuance system for driver,s licenses ... The project planning and development will start in January ...
(Date:1/22/2015)... 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), the ... campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz will ... capacity to meet customer demand. Logo ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by Dr. ...
Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3Valid USA Signs Contract For Washington Driver's License Issuance 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2
... Ariz. Nearly 675 strong, American colleges and universities ... neutralize carbon dioxide emissions on their campuses that contribute ... curriculum. But how do you get from commitment to ... focus of the 2012 Southwest Regional Collaborative Symposium of ...
... to rapid and extensive changes in genome function. A ... that the changes are heritable, although they do not ... as livestock about 8000 years ago. Evolutionarily speaking, the ... of different colours, shapes and sizes has occurred in ...
... COLLEGE PARK, Md. - Scientists from the University ... track and predict the impact of climate change internationally. ... and predictive tools that can help, for example, predict ... in preparations for shortages, organizers say. At the ...
Cached Biology News:American College and University Presidents' Climate Commitment to meet at Arizona State University 2Inherited epigenetics produced record fast evolution 2UMD and Chinese partner to track and predict world climate change 2
... GELase™ Agarose Gel-Digesting Preparation contains a ... for simple, quantitative recovery of intact DNA ... agarose gels following electrophoresis in TAE, TBE, ... be digested directly in the TAE, TBE, ...
... Perhaps sheer in-house demand is causing ... your precious antibody. This can cause unwanted ... Receive royalties for your hard ... and let us build it up,and market ...
... a recombinant preparation of the catalytic subunit ... expressed and isolated from the yeast Pichia ... preparation (2). It recognizes the sequence Asp-Asp-Asp-Asp-Lys ... lysine residue. The enzyme can be used ...
... Perhaps sheer in-house demand is causing ... your precious antibody. This can cause unwanted ... Receive royalties for your hard ... and let us build it up,and market ...
Biology Products: